Cash Burn Rate for Pre-Profit IPO Companies: How Long Can They Survive

The HKEX’s 2024 amendments to the Listing Rules, which took full effect for applications submitted on or after 1 January 2025, have codified a long-standing de facto practice: pre-revenue biotech sponsors must now formally demonstrate a 12-month cash runway from the date of listing. This regulatory hardening, combined with the elevated interest rate environment (the HIBOR 1-month fixing averaged 4.15% in Q1 2025, compared to 0.25% in Q1 2022), has transformed cash burn analysis from a footnote in the risk factors section into the single most important metric for underwriting pre-profit IPO companies. For sponsors, analysts, and investors evaluating Chapter 18C (Specialist Technology Companies) or Chapter 18A (Biotech) applicants, the question is no longer whether the company has a viable product, but precisely how many months of liquidity remain before a dilutive follow-on is mathematically inevitable.

The Regulatory Framework: HKEX’s Cash Runway Requirements

Chapter 18A and 18C Codification

The HKEX’s Listing Decision LD143-2023 and the subsequent rule amendments effective 1 January 2025 require all pre-revenue applicants under Chapter 18A (Biotech) and Chapter 18C (Specialist Technology Companies) to include in their prospectus a formal cash runway statement. This statement must demonstrate, based on the sponsor’s base-case financial projections, that the group has sufficient working capital for at least 125% of the 12-month period following the listing date. The 25% buffer above the 12-month minimum is a direct response to the 2022-2023 cycle where three pre-profit biotech issuers — including one that had raised HKD 1.8 billion in its 2021 IPO — breached their cash covenants within nine months of listing.

The cash runway calculation methodology is specified in HKEX Guidance Letter GL112-23. The calculation must include all committed operating expenditures (R&D, CRO contracts, manufacturing scale-up), capital expenditure commitments (laboratory equipment, facility leases), and debt service obligations (principal and interest on convertible notes or bank facilities). The sponsor must also disclose the key assumptions underpinning the base-case scenario, including revenue recognition timing, gross margin progression, and operating expense growth rates. Any deviation of more than 15% from the projections in the first two post-listing interim reports triggers an automatic disclosure obligation under Listing Rule 13.09.

The Sponsor’s Liability Exposure

The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Chapter 571, subsidiary legislation) imposes a heightened duty of care on sponsors for cash runway assessments. Paragraph 17.6 of the Code requires the sponsor to conduct independent verification of the issuer’s cash flow projections, including cross-referencing CRO contracts with actual payment histories and confirming that committed capex is funded by identifiable sources. In the 2024 enforcement action against ABCI Capital Limited (SFC press release, 15 March 2024), the SFC fined the sponsor HKD 12 million for failing to adequately verify a pre-revenue biotech applicant’s claim that it had 18 months of cash runway, when the sponsor’s own sensitivity analysis showed only 11 months under a moderate downside scenario.

For sponsors, the practical implication is that the cash burn analysis must now be stress-tested across three scenarios: base case (management projections), downside case (20% revenue shortfall, 10% cost overrun), and severe case (40% revenue shortfall, 25% cost overrun). The prospectus must disclose the cash runway under each scenario, and the sponsor’s legal opinion must confirm that the issuer can meet its obligations for at least 12 months even under the severe case.

Calculating Cash Burn: Methodologies and Pitfalls

Gross Burn vs. Net Burn

The distinction between gross burn and net burn is frequently misstated in prospectus summaries, leading to material misperceptions. Gross burn equals total operating cash outflows per period — including R&D, SG&A, and capex — before any cash inflows from operations. Net burn subtracts operating cash inflows (product sales, licensing fees, milestone payments) from gross burn. For a pre-revenue biotech with no commercial product, gross burn and net burn are identical; for a pre-profit specialist technology company with early-stage revenue, the difference can be substantial.

Take the example of a Chapter 18C applicant in the AI semiconductor space that filed its A1 application in February 2025. The prospectus disclosed a gross burn of HKD 420 million per quarter and a net burn of HKD 280 million per quarter, reflecting HKD 140 million in quarterly licensing revenue from a single customer. The cash runway based on gross burn was 8.5 months, while the net burn runway was 12.8 months. The sponsor, applying the SFC Code of Conduct paragraph 17.6, required the issuer to separately disclose the cash runway excluding the single customer’s revenue, which reduced the net burn runway to 9.2 months. This single-customer concentration risk was flagged as a key risk factor in the prospectus summary.

The Trap of Non-Cash Items

A recurring error in cash burn analysis — one that has triggered multiple SFC inquiries — is the inclusion of non-cash charges in the burn calculation. Share-based compensation, depreciation, and amortisation do not consume cash and must be excluded from the burn rate. In the 2023 prospectus of a GEM-listed biotech, the issuer initially reported a quarterly cash burn of HKD 95 million, which included HKD 22 million in share-based compensation and HKD 8 million in depreciation. The adjusted cash burn, excluding these non-cash items, was HKD 65 million — a 31.6% reduction that extended the implied cash runway from 14 months to 20 months. The SFC required a supplementary filing correcting the error before the listing could proceed.

Sponsors should also scrutinise capitalised R&D expenditures. Under HKAS 38, development costs that meet the recognition criteria (technical feasibility, intent to complete, ability to use or sell, etc.) are capitalised as intangible assets. These capitalised amounts are not reflected in the cash flow statement as operating outflows but appear in the investing activities section. A company with aggressive capitalisation policies may show a lower operating cash burn than its true cash consumption. The sponsor must reconcile the capitalised R&D with actual cash outflows to arrive at the true burn rate.

Survival Analysis: The 12-Month Cliff

The Dilution Spiral

A pre-profit company with less than 12 months of cash runway at listing faces a structurally impaired capital structure. The mathematics are straightforward: if a company has HKD 500 million in cash at listing and burns HKD 100 million per quarter, it has 5 quarters of runway. Assuming it needs to raise additional capital in quarter 4 to avoid a cash crisis, the company will be negotiating from a position of weakness. Distressed equity raisings in Hong Kong have historically been priced at a 30-50% discount to the IPO price, with warrants or conversion features that further dilute existing shareholders.

The HKEX’s Listing Rule 13.36 requires that any issuance of new shares exceeding 20% of the existing issued share capital must be approved by independent shareholders. For a company in a cash crisis, obtaining this approval becomes difficult as institutional investors, particularly those who participated in the IPO, may block the resolution to force a lower price. This dynamic was observed in the case of a pre-profit biotech that listed in November 2022 with 14 months of cash runway. By month 10, with only 4 months of cash remaining, the company attempted a rights issue at a 45% discount to the prevailing market price. The independent shareholders rejected the proposal, and the company was forced to accept a bridge loan at 12% per annum secured against its intellectual property.

Sector-Specific Burn Profiles

The cash burn analysis must be contextualised within the specific sector’s operating model. For Chapter 18A biotech companies, the primary cost driver is CRO and CMO contracts, which are typically denominated in USD and have 12-24 month commitment periods. A biotech with a Phase 2 clinical trial underway will have committed expenditures of approximately HKD 80-150 million per trial, with payments spread over 18-24 months. The cash burn rate is therefore not linear but lumpy, with peak burn occurring during patient enrolment and data collection phases.

For Chapter 18C specialist technology companies, the burn profile is more evenly distributed across R&D headcount (typically 60-70% of total burn), cloud computing or data centre costs (15-20%), and sales and marketing (10-15%). A pre-profit AI company with 200 R&D engineers in Hong Kong and Shenzhen would have a quarterly burn of approximately HKD 50-70 million, primarily driven by salaries, server costs, and office rent. The survival analysis must factor in the time required to recruit and train replacement talent if the company needs to downsize, as the notice period for R&D staff in Hong Kong is typically 1-3 months, and severance costs can add 10-15% to the quarterly burn.

Practical Implications for Sponsors and Investors

The 24-Month Rule of Thumb

Market practice among Hong Kong sponsors has converged on a 24-month minimum cash runway as the de facto underwriting standard, even though the HKEX rules only require 12 months. This is driven by two factors: first, the average time from A1 submission to listing is 4-6 months, meaning that a company with exactly 12 months of runway at listing will have only 6-8 months of cash remaining by the time it begins trading. Second, institutional investors in pre-IPO placements — particularly cornerstone investors under the HKEX’s Guidance Letter GL51-13 — increasingly demand a 24-month runway as a condition of their participation.

The data supports this conservatism. A 2024 analysis by a major Hong Kong law firm of 47 pre-profit IPOs listed between 2020 and 2024 found that companies with less than 18 months of cash runway at listing had a 34% probability of requiring a dilutive follow-on offering within 12 months of listing, compared to 8% for companies with more than 24 months of runway. The average dilution for the distressed group was 38% of pre-offering share capital, versus 12% for the well-capitalised group.

The Role of the Cash Runway Statement in Valuation

The cash runway statement directly impacts the IPO valuation. For a pre-profit company, the enterprise value is a function of the probability-weighted net present value of future cash flows, discounted at a rate that includes the risk of failure. The cash runway is the primary input for estimating the probability of failure: a company with 12 months of runway has a higher implied probability of distress than one with 36 months. In practice, sponsors apply a 5-10% discount to the DCF-derived valuation for each year of cash runway below 36 months.

This creates a structural tension: the company wants to maximise the IPO proceeds to extend its runway, but the valuation discount applied for a short runway reduces the proceeds, creating a circular reference. The solution, as adopted by several 2024 Chapter 18C listings, is to structure the IPO with an over-allotment option (Greenshoe) of up to 15% of the base offering size, with the proceeds from the over-allotment specifically earmarked to extend the cash runway beyond the 24-month threshold.

Actionable Takeaways

1. Cash runway must be calculated on a net basis excluding non-cash items, and the sponsor must stress-test the runway under at least three scenarios per the SFC Code of Conduct paragraph 17.6, with the severe case showing at least 12 months of survival.
2. A pre-profit IPO company with less than 24 months of cash runway at listing has a 34% probability of a dilutive follow-on within 12 months, based on 2020-2024 Hong Kong listing data, making this the single most important metric for institutional investors.
3. The cash burn analysis must account for lumpy expenditure patterns — particularly CRO/CMO contracts for biotech and cloud infrastructure for tech — rather than assuming linear monthly burn, as the timing of peak cash consumption can shift the survival analysis by 2-3 months.
4. Sponsors must independently verify the issuer’s cash flow projections against third-party contracts and payment histories, as the SFC’s 2024 enforcement action against ABCI Capital demonstrated that failure to do so carries a HKD 12 million penalty.
5. The IPO valuation must incorporate a 5-10% discount per year of cash runway below 36 months, and the over-allotment option should be structured to extend the runway beyond the 24-month threshold to avoid the circular reference between valuation and proceeds.